Amazon study reveals most European employees favour on-the-job skills training or apprenticeships over university degrees for a successful career start
13.6.2024 17:38:00 EEST | Business Wire | Press release
More than half of European workers (54%) believe that on-the-job-skills training or apprenticeships are more valuable for preparing people for work today than traditional university degrees, a new European career insights and workplace trends study commissioned by Amazon has found. In fact, the study found that just under three quarters (73%) of workers feel there needs to be a wider range of apprenticeship or internship opportunities available to young people.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613014196/en/
The Amazon Future of Work & Career Development European study, conducted by Ipsos, also found that a majority of European employees* (89%) think it’s important to learn a new skill to improve or change their career path, even more so than receiving a promotion (73%). Alongside factors such as pay/salary (94%) and office/worksite location or flexible/hybrid or remote working (93%), 91% of adults say on the job training or career development training is essential or important when looking for a new job or role, and that training programmes offered by a potential employer are more important than company culture (78%). One potential reason is that many workers in the study said it would make them feel motivated (39%), encouraged (32%), valued (31%) or supported (30%) to work for a company that provides access to career development training. Additionally, almost one in five workers in Europe (19%) admit they couldn’t afford to pay for training.
Amazon has long adapted to the ever-changing career and education landscape, investing more than €100 million in training programmes in Europe since it launched its Career Choice programme in the region in 2014. The programme provides 95% of pre-paid tuition, up to €8,000 over four years, for nationally recognised courses from more than 85 schools throughout Europe. It offers various training opportunities in a range of popular, in-demand job fields, from tech and sustainability to business administration and logistics, for Amazon’s hourly and salaried workers across the region.
To mark the ten-year anniversary of Career Choice in Europe, Amazon plans to invest €40 million in 2024 and to add more than 25 new programmes across five countries in Europe this year to support current and future job needs for the thousands of employees who participate in Career Choice. Currently, Amazon employees in Europe have access to over a hundred different programmes to help them maximise their potential within the company or outside of Amazon. Some of the new courses added in 2024 include Cloud Support, Cyber Security, Information Security, Web and Graphic Design, Mechatronics, Procurement Logistics, and Big Data, Virtualisation, and Machine Learning.
Since its launch ten years ago, more than 40,000 Amazon employees across Europe** have participated in the programme. While some employees leave Amazon to pursue other career opportunities with their newly acquired skills and certifications from Career Choice, thousands have stayed and transitioned into new roles. The popularity of the programme continues to increase, with about one in ten of all eligible employees in Europe participating in Career Choice in 2023. Popular areas of study vary from technology and sustainability, to mechanical and industrial systems, transportation and logistics, and administration and business studies.
“I attribute a lot of my growth at Amazon to Career Choice,” said Mo Abdullahi, Senior Operations Manager and Career Choice participant number four in the UK from 2014. “It gave me an opportunity to learn more about the role that I wanted and helped me with obtaining the qualifications that I needed. I'm still super surprised of my journey and growth through Amazon. If I look back ten years ago and starting as a temporary worker, I certainly wouldn't have assumed that I would be at the level I am right now and with the responsibility I have now. It’s been an incredible journey.”
When it comes to jobs in the future, the study shows that training will need to play a key role in alleviating worker concerns, as 32% of European workers are worried they won’t have the training and skills to be relevant in their job in the coming years. In fact, two-thirds of European workers (67%) believe that people in the workforce today will need to continue to retrain and update their skills to continue working in the future. However, only 15% of employees say they have access to training to help them change their career path, and over one in five (22%) employees say they don’t have any access to training with their current employer.
“The latest research and the growth of our Career Choice programme over the past ten years clearly demonstrates the strong desire for workers across the Europe to develop their careers through relevant and accessible skills training programmes,” said Robert Marhan, Global Operations Vice President of People Experience & Technology (PXT). “Amazon is proud to celebrate the tenth anniversary of the Career Choice skills training programme in Europe and to expand the course options available, so that thousands of employees across Europe can advance their skills and take on new career opportunities both at Amazon and beyond.”
The Career Choice programme is currently available to Amazon employees in Australia, Canada, Costa Rica, Czech Republic, France, Germany, Ireland, Italy, Poland, Slovakia, South Africa, Spain, the U.S., and the UK. It has a rigorous selection process for third-party partner educators, choosing partners that are focused on helping employees through their education programmes, assisting them with job placements, and overall offering education that leads to career success.
To learn more about the Career Choice programme, visit Amazon Career Choice https://www.aboutamazon.eu/news/tag/working-at-amazon/career-choice
Sources:
*The research was carried out by Ipsos UK on behalf of Amazon. Ipsos UK interviewed a representative quota sample of 16,482 adults using its online omnibus, and within that a sample of 9,686 employees. Fieldwork was carried out in 8 markets across Europe, including Spain, Germany, UK, France, Italy, Slovakia, Czech Republic, Poland. The sample achieved is representative of the population aged 16-75 in all markets except Czech Republic and Slovakia, where the participants were aged 16-65. Interlocking quotas were set on Age within Gender, and on Region and Working status. The data has been weighted to the known offline population proportions for interlocking cells of gender within age and working status, as well as region and education to reflect the adult population of each market. A country average weight was also applied. Fieldwork was carried out between the 26th April and 27th May 2024. This research was conducted as part of a global study across Australia, Canada, Czech Republic, France, Germany, Italy, Poland, South Africa, Slovakia, Spain, and the UK.
**Amazon Career Choice participation data collected in Europe between 2014-24.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613014196/en/
Contacts
Louise Thach thachl@amazon.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom